PTPRK
Receptor-type tyrosine-protein phosphatase kappa
Protein Summary
Regulation of processes involving cell contact and adhesion such as growth control, tumor invasion, and metastasis. Negative regulator of EGFR signaling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin. Beta-catenin may be a substrate for the catalytic activity of PTPRK/PTP-kappa. The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain and four fibronectin type III-like repeats. This PTP was shown to mediate homophilic intercellular interaction, possibly through the interaction with beta- and gamma-catenin at adheren ...more
- ENST00000368213
- ENSP00000357196
- ENSG00000152894
- ENST00000368215
- ENSP00000357198
- ENST00000368226
- ENSP00000357209
- ENST00000532331
- ENSP00000432973
- ENST00000618215
- ENSP00000484742
- ENSG00000273993
- ENST00000618924
- ENSP00000483766
- ENST00000619256
- ENSP00000477791
- ENST00000628183
- ENSP00000486442
- PTPK
- R-PTP-kappa
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 1 | ||
trait | 0.97 | ||
transcription factor perturbation | 0.94 | ||
biological process | 0.82 | ||
disease perturbation | 0.79 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 43.78 (req: < 5)
Gene RIFs: 33 (req: <= 3)
Antibodies: 46 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 43.78 (req: >= 5)
Gene RIFs: 33 (req: > 3)
Antibodies: 46 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 20
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0